Skip to main content
Kolon TissueGene, Inc. logo

Kolon TissueGene, Inc. — Investor Relations & Filings

Ticker · 950160 ISIN · KR8840120008 LEI · 5493000SYYLC88FUL781 KO Manufacturing
Open in API
Filings indexed 288 across all filing types
Latest filing 2020-03-31 Audit Report / Informat…
Country US United States of America
Listing KO 950160

About Kolon TissueGene, Inc.

https://www.tissuegene.com/

Kolon TissueGene, Inc. is a clinical-stage biopharmaceutical company specializing in the development of advanced cell and gene therapies for orthopedic diseases and degenerative disorders. The company's lead product candidate, TG-C, is a first-in-class, allogeneic cell and gene therapy designed to treat knee osteoarthritis. The therapy aims to reduce pain, improve joint function, and slow the progression of the disease. TG-C is currently in late-stage clinical development, undergoing Phase 3 trials.

Recent filings

Filing Released Lang Actions
투자판단관련주요경영사항(2020년 감사인 미선임관련 )
Audit Report / Information Classification · 95% confidence The document is a short regulatory disclosure from Kolon TissueGene regarding the failure to appoint an auditor for the 2020 fiscal year within the required timeframe. It is a specific corporate announcement regarding regulatory compliance and management status, which does not fit into financial reporting or specific event categories like M&A or dividends. Therefore, it falls under the general regulatory filing category. Q1 2020
2020-03-31 Korean
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 100% confidence The document is a regulatory filing titled '사외이사의 선임ㆍ해임 또는 중도퇴임에 관한 신고' (Report on the Appointment, Dismissal, or Resignation of Outside Directors). This document specifically details changes to the company's board of directors, which falls under the category of Board/Management Information (MANG).
2020-03-25 Korean
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 100% confidence The document is a regulatory filing titled '사외이사의 선임ㆍ해임 또는 중도퇴임에 관한 신고' (Report on the Appointment, Dismissal, or Resignation of Outside Directors). It details the appointment of an outside director (Jang-ik Lee) for Kolon TissueGene. This falls under the category of board management and changes in corporate governance structure, which is classified as MANG (Board/Management Information).
2020-03-25 Korean
기타시장안내(상장폐지 관련 이의신청서 접수)
Regulatory Filings Classification · 95% confidence The document is a short regulatory announcement from the Korea Exchange regarding Kolon TissueGene's submission of an objection letter concerning a potential delisting. It does not constitute the delisting itself, but rather an update on the regulatory process following an audit opinion issue. As it is a regulatory notice regarding market status and listing procedures, it falls under the RNS category.
2020-03-25 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an official report of the results of a General Meeting of Shareholders (정기주주총회결과). It details the outcomes of voting on agenda items such as financial statement approval, director and auditor appointments, and remuneration limits. This falls directly under the definition of a Declaration of Voting Results & Voting Rights Announcement.
2020-03-24 Korean
대표이사변경
Board/Management Information Classification · 100% confidence The document is a formal announcement regarding the appointment of a new co-CEO (Han Sung-soo) and the change in the board/management structure of Kolon TissueGene. It explicitly lists the 'Change of Representative Director' (대표이사변경) as the primary subject, which falls under the category of Board/Management Information.
2020-03-24 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.